l-Arginine treatment for severe vascular fetal intrauterine growth restriction: A randomized double-bind controlled trial

Clinical Nutrition

Volumn 28, Issue 3, 2009, Pages 243-248

  Winer, Norbert ^a,f   Branger, Bernard ^b   Azria, Elie ^c   Tsatsaris, Vassilis ^c   Philippe, Henri Jean ^a   Rozé, Jean Christophe ^a,f   Descamps, Philippe ^d   Boog, Georges ^a   Cynober, Luc ^e   Darmaun, Dominique ^f  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Perinatal Health Network   (France)

^c Department of Obstetrics and Gynecology Descartes University Paris 5 ^*  (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e University Paris Descartes   (France)

^f Universite de Nantes   (France)

Author keywords

l Arginine; Nitric oxide donor; Severe growth retardation with pathologic uterine Doppler

Indexed keywords

ARGININE; PLACEBO;

ADULT; ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENTERIC FEEDING; FEMALE; FETUS; FETUS ECHOGRAPHY; HUMAN; INTRAUTERINE GROWTH RETARDATION; MALE; MULTICENTER STUDY; NEWBORN; NEWBORN MORBIDITY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ARGININE; BIRTH WEIGHT; DOUBLE-BLIND METHOD; FEMALE; FETAL GROWTH RETARDATION; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; MALE; MORBIDITY; NITRIC OXIDE; PLACENTA; PREGNANCY; TREATMENT OUTCOME; ULTRASONOGRAPHY, PRENATAL; VASODILATION;

EID: 67349136340     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2009.03.007     Document Type: Article

References (58)

1. Gilbert W.M., and Danielsen B. Pregnancy outcomes associated with intrauterine growth restriction. Am J Obstet Gynecol 188 (2003) 1596-1599
2. Villar J., Carroli G., and Wojdyla D. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions?. Am J Obstet Gynecol 194 (2006) 921-931
3. Laurini R., Laurin J., and Marsal K. Placental histology and fetal blood flow in intrauterine growth retardation. Acta Obstet Gynecol Scand 73 (1994) 529-534
4. Lumbers E.R., Yu Z.Y., and Gibson K.J. The selfish brain and the Barker hypothesis. Clin Exp Pharmacol Physiol 28 (2001) 942-947
5. Aucott S.W., Donohue P.K., and Northington F.J. Increased morbidity in severe early intrauterine growth restriction. J Perinatol 24 (2004) 435-440
6. Simchen M.J., Beiner M.E., Strauss-Liviathan N., Dulitzky M., Kuint J., Mashiach S., et al. Neonatal outcome in growth-restricted versus appropriately grown preterm infants. Am J Perinatol 17 (2000) 187-192
7. Pedersen C.B., Sun Y., Vestergaard M., Olsen J., and Basso O. Assessing fetal growth impairments based on family data as a tool for identifying high-risk babies. An example with neonatal mortality. BMC Pregnancy Childbirth 7 (2007) 28
8. Valcamonico A., Accorsi P., Sanzeni C., Martelli P., La Boria P., Cavazza A., et al. Mid- and long-term outcome of extremely low birth weight (ELBW) infants: an analysis of prognostic factors. J Matern Fetal Neonatal Med 20 (2007) 465-471
9. Boulet S.L., Alexander G.R., Salihu H.M., Kirby R.S., and Carlo W.A. Fetal growth risk curves: defining levels of fetal growth restriction by neonatal death risk. Am J Obstet Gynecol 195 (2006) 1571-1577
10. Ross M.G., and Beall M.H. Adult sequelae of intrauterine growth restriction. Semin Perinatol 32 (2008) 213-218
11. Frankel S., Elwood P., Sweetnam P., Yarnell J., and Davey Smith G. Birthweight, body-mass index in middle age, and incident coronary, heart disease. Lancet 348 (1996) 1478-1480
12. Osmond C., and Barker D.J. Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women. Environ Health Perspect 108 (2000) 545-553
13. Thompson J.N. Fetal nutrition and adult hypertension, diabetes, obesity, and coronary artery disease. Neonatal Netw 26 (2007) 235-240
14. Uzan S., Beaufils M., Breart G., Bazin B., Capitant C., and Paris J. Prevention of foetal growth retardation with low-dose aspirin. Lancet 337 (1991) 1427-1431
15. Duley L., Henderson-Smart D.J., Knight M., and King J.F. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 1 (2004) CD004659
16. Wu G., and Morris Jr. S.M. Arginine metabolism: nitric oxide and beyond. Biochem J 15 336 (1998) 1-17
17. Appleton J. Arginine: clinical potential of a semi-essential amino. Altern Med Rev. 7 (2002) 512-522
18. Moinard C., Cynober L., and De Bandt J.P. Polyamines metabolism and implications in human diseases. Clin Nutr 24 (2005) 184-197
19. Wu G., Bazer F.W., Cudd T.A., Meininger C.J., and Spencer T.E. Maternal nutrition and fetal development. J Nutr 134 (2004) 2169-2172
20. Wu G., Jaeger L.A., Bazer F.W., and Rhoads J.M. Arginine deficiency in preterm infants: biochemical mechanisms and nutritional implications. J Nutr Biochem 15 (2004) 442-451
21. Levin E.R. Endothelins. N Eng J Med 333 (1995) 356-363
22. Vosatka R.J., Hassoun P.M., and Harvey-Wilkes K.B. Dietary l-arginine prevents fetal growth restriction in rats. Am J Obstet Gynecol 178 (1998) 242-246
23. Helmbrecht G.D., Farhat M.Y., Lochbaum L., Yadgarova K.T., Eglinton G.S., and Ramwell P.W. l-Arginine reverses the adverse pregnancy changes induced by nitric oxide synthase inhibition in the rat. Am J Obstet Gynecol 175 (1996) 800-805
24. Wu G., Meininger C.J., Knabe D.A., Bazer F.W., and Rhoads J.M. Arginine nutrition in development, health and disease. Curr Opin Clin Nutr Metab Care 3 (2000) 59-66
25. Wolf G. Adult type 2 diabetes induced by intrauterine growth retardation. Nutr Rev. 61 (2003) 176-179
26. Martina V., Masha A., Gigliardi V.R., Brocato L., Manzato E., Berchio A., et al. Long-term N-acetylcysteine and l-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care 31 (2008) 940-944
27. Shah P., and Shah V. Arginine supplementation for prevention of necrotising enterocolitis in preterm infants. Cochrane Database Syst Rev 3 (2007) CD004339
28. Lampariello C., De Blasio A., Merenda A., Graziano E., Michalopoulou A., and Bruno P. Use of l-arginine in intra uterine growth retardation (IUGR): author's experience. Minerva Gynecol 49 (1997) 577-581
29. Neri I., Mazza V., Galassi M.C., Volpe A., and Facchinetti F. Effects of l-arginine on utero-placental circulation in growth-retarded fetuses. Acta Obstet Gynecol Scand 75 (1996) 208-212
30. Meher S., and Duley L. Nitric oxide for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev (2007) CD006490
31. J.Créquat M., and DuymeBrodaty G. Biometry 2000. Fetal growth charts by the French College of fetal ultrasonography and the Inserm U 155. Gynecol Obstet Fertil 28 (2000) 435-445
32. Dawes G.S., Moulden M., and Redman C.W.G. Short-term fetal heart rate variations, decelerations, and umbilical flow velocity waveforms before labor. Obstet Gynecol 80 (1992) 673-678
33. Usher R., and McLean F. Intrauterine growth of live-born Caucasian infants at sea-level: standard obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks gestation. J Pediatr 74 (1969) 901-910
34. Kramer M.S., Platt R.W., Wen S.W., Joseph K.S., Allen A., Abrahamowicz M., et al., Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance System. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics 108 (2001) E35
35. Mamelle N., Munoz F., and Grandjean H. Fetal growth from the AUDIPOG study. I. Establishment of reference curves. J Gynecol Obstet Biol Reprod 25 (1996) 61-70
36. Moncada S., Radomski M.W., and Palmer R.M. Endothelium-derived relaxing factor identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol 37 (1988) 2495-2501
37. Xiao X.M., and Li L.P. l-Arginine treatment for asymmetric fetal growth restriction. Int J Gynecol Obstet 88 (2005) 15-18
38. Lyall F., Greer I.A., Young A., and Myatt L. Nitric oxide concentrations are increased in the feto-placental circulation in intrauterine growth restriction. Placenta 17 (1996) 165-168
39. Sieroszewski P., Suzin J., and Karowicz-Billinska A. Ultrasound evaluation of intra uterine growth restriction therapy by a nitric oxide donor (l-arginine). J Matern Fetal Neonatal Med 15 (2004) 363-366
40. Espinoza J., Romero R., Nien J.K., Gomez R., Kusanovic J.P., Gonçalves L.F., et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 196 (2007) 326 e1-e13
41. Yallampalli G., and Garfield R.E. Inhibition of nitric oxide synthesis during pregnancy produces signs similar to those of preeclampsia. Am J Obstet Gynecol 169 (1993) 1316-1320
42. Zimmermann P., Eiriö V., Koskinen J., Kujansuu E., and Ranta T. Doppler assessment of the uterine and uteroplacental circulation in the second trimester in pregnancies at high risk for pre-eclampsia and/or intrauterine growth retardation: comparison and correlation between different Doppler parameters. Ultrasound Obstet Gynecol 9 (1997) 330-338
43. Rytlewski K., Olszanecki R., Lauterbach R., Grzyb A., and Basta A. Effects of oral l-arginine on the foetal condition and neonatal outcome in preeclampsia: a preliminary report. Basic Clin Pharmacol Toxicol 99 (2006) 146-152
44. Lees C., Langford E., Brown A.S., de Belder A., Pickles A., Martin J.F., and Campbell S. The effects of S-nitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. Obstet Gynecol 88 (1996) 14-19
45. Thaler I., Amit A., Kamil D., and Itskovitz-Eldor J. The effect of isosorbide dinitrate on placental blood flow and maternal blood pressure in women with pregnancy induced hypertension. Am J Hypertens 12 (1999) 341-347
46. Bryan N.S., and Grisham M.B. Methods to detect nitric oxide and its metabolites in biological samples. Free Radic Biol Med 43 (2007) 645-657
47. Thaete L.G., Kushner D.M., Dewey E.R., and Neerhof M.G. Endothelin and the regulation of uteroplacental perfusion in nitric oxide synthase inhibition-induced fetal growth restriction. Placenta 26 (2005) 242-250
48. Van de Poll M.C., Ligthart-Melis G.C., Boelens P.G., Deutz N.E., van Leeuwen P.A., and Dejong C.H. Intestinal and hepatic metabolism of glutamine and citrulline in humans. J Physiol 581 (2007) 819-827
49. Curis E., Nicolis I., Moinard C., Osowska S., Zerrouk N., Bénazeth S., et al. Almost all about citrulline in mammals. Amino Acids 29 (2005) 177-205
50. Rougé C., Des Robert C., Robins A., Le Bacquer O., Volteau C., De La Cochetière M.F., and Darmaun D. Manipulation of citrulline availability in humans. Am J Physiol 293 (2007) G1061-G1067
51. Moinard C., Nicolis I., Neveux N., Darquy S., Bénazeth S., and Cynober L. Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. Br J Nutr 99 (2008) 855-862
52. Smith H.A., Canter J.A., Christian K.G., Drinkwater D.C., Scholl F.G., Christman B.W., et al. Nitric oxide precursors and congenital heart surgery: a randomized controlled trial of oral citrulline. J Thorac Cardiovasc Surg 132 (2006) 58-65
53. Ishikawa T., Harada T., Koi H., Kubota T., Azuma H., and Aso T. Identification of arginase in human placental villi. Placenta 28 (2007) 133-138
54. Paolini C.L., Marconi A.M., Ronzoni S., Di Noio M., Fennessey P.V., Pardi G., et al. Placental transport of leucine, phenylalanine, glycine, and proline in intrauterine growth-restricted pregnancies. J Clin Endocrinol Metab 86 (2001) 5427-5432
55. Grillo M.A., Lanza A., and Colombatto S. Transport of amino acids through the placenta and their role. Amino Acids 34 (2008) 517-523
56. Casanello P., and Sobrevia L. Intrauterine growth retardation is associated with reduced activity and expression of the cationic amino acid transport systems y+/hCAT-1 and y+/hCAT-2B and lower activity of nitric oxide synthase in human umbilical vein endothelial cells. Circ Res 91 (2002) 127-134
57. Savvidou M., Hingorani A., Tsikas D., Frölich J., Vallance P., and Nicolaides K. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 361 (2003) 1511-1517
58. De Pace V., Chiossi G., and Facchinetti F. Clinical use of nitric oxide donors and l-arginine in obstetrics. J Matern Fetal Neonatal Med 20 (2007) 569-579